US Pharma MarketingIntismeran autogene a turning point for cancer vaccines
On 19 August, Moderna announced interim analysis data from a Phase III trial for intismeran autogene, a personalised mRNA neoantigen cancer vaccine.
On 19 August, Moderna announced interim analysis data from a Phase III trial for intismeran autogene, a personalised mRNA neoantigen cancer vaccine.
Source: Pharmaceutical Technology